Tag Archives: Eisai

Belviq's Battle of the Bulge

Arena Pharmaceuticals’ and marketing partner Eisai’s Belviq – the first FDA-approved drug to treat obesity in over a decade – is making progress with payers and beefing up sales forces to target primary care physicians. DTC support began in September. Perhaps the most significant development in obesity of late is the recognition by payers – […]
Posted in Advertising, FDA, Global, healthcare, Market Access, Marketing, Patient Communication, People, pricing, Regulatory, Safety, Sales, Strategy | Also tagged , , , , , , , , , , , , , | Leave a comment

Conversation with Eisai’s Lonnel Coats

“The phones are ringing,” said Lonnel Coats, president of Eisai and a plenary speaker here at HBA’s Leadership Conference. “There’s a lot more opportunity, but also a lot more white noise.” Coats is referring to the pressure that cash-strapped biotechs are feeling to sell out and says he gets no less than five calls a […]
Posted in Events, Strategy | Also tagged , , , , | Leave a comment
  • Categories

  • Meta